The estimated Net Worth of Max Reinhardt is at least $7.21 Million dollars as of 6 June 2023. Mr. Reinhardt owns over 2,153 units of Pacira BioSciences Inc stock worth over $379,925 and over the last 5 years he sold PCRX stock worth over $2,251,107. In addition, he makes $4,575,040 as President at Pacira BioSciences Inc.
Max has made over 10 trades of the Pacira BioSciences Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 2,153 units of PCRX stock worth $82,718 on 6 June 2023.
The largest trade he's ever made was exercising 37,500 units of Pacira BioSciences Inc stock on 18 April 2022 worth over $1,595,250. On average, Max trades about 8,088 units every 71 days since 2019. As of 6 June 2023 he still owns at least 29,225 units of Pacira BioSciences Inc stock.
You can see the complete history of Mr. Reinhardt stock trades at the bottom of the page.
Max Reinhardt serves as President of the Company. Prior to joining Pacira, he served as Vice President of Marketing for DePuy Synthes Sales, Inc. ("DePuy Synthes"), part of the Johnson & Johnson Medical Devices Companies ("Johnson & Johnson"), from March 2016 until May 2019. Prior to serving as Vice President of Marketing at DePuy Synthes, Mr. Reinhardt was Director of Sales and Marketing for DePuy Spine and Vice President of US Sales for DePuy Spine. In 2011, he was named Vice President, Worldwide Marketing of DePuy Synthes, a position in which he played a key role in the acquisition and integration of Synthes Spine. In 2012, he was named Worldwide President, DePuy Synthes Spine, and led the spine business through the first two years of integration. Prior to Johnson & Johnson, Mr. Reinhardt served in sales leadership roles at both Olympus KeyMed and STERIS Corporation in the United Kingdom.
As the President of Pacira BioSciences Inc, the total compensation of Max Reinhardt at Pacira BioSciences Inc is $4,575,040. There are 1 executives at Pacira BioSciences Inc getting paid more, with David Stack having the highest compensation of $5,806,430.
Max Reinhardt is 49, he's been the President of Pacira BioSciences Inc since 2019. There are 20 older and 5 younger executives at Pacira BioSciences Inc. The oldest executive at Pacira BioSciences Inc is Gary Pace, 72, who is the Independent Director.
Max's mailing address filed with the SEC is 3451 PLANO PARKWAY, , LEWISVILLE, TX, 75056.
Over the last 14 years, insiders at Pacira BioSciences Inc have traded over $321,391,130 worth of Pacira BioSciences Inc stock and bought 2,075,444 units worth $15,133,188 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Carl L Gordon und Andreas Wicki. On average, Pacira BioSciences Inc executives and independent directors trade stock every 13 days with the average trade being worth of $491,036. The most recent stock trade was executed by Marcelo Bigal on 16 August 2024, trading 1,512 units of PCRX stock currently worth $20,034.
pacira pharmaceuticals, inc. (nasdaq: pcrx) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. the company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, exparel® (bupivacaine liposome injectable suspension), was commercially launched in the united states in april 2012. exparel and two other products have utilized the pacira proprietary product delivery technology depofoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.
Pacira BioSciences Inc executives and other stock owners filed with the SEC include: